



## **CERTIFICATE OF ANALYSIS No.: 2022-10252**


## **CLIENT**

CIITECH Ltd, 2 Athenaeum Road GB-N20 9AE London, United Kingdom

## SAMPLE \*

Provacan CBD Oil - Boosted Terpenes 2400mg / 10ml





Sample condition:	SUITABLE	Work order:	2022-107030	Sample received:	26/10/2022
Sample ID:	2243035	Analysis ID:	2022_245 and 246	Start of analysis:	26/10/2022
Sample type:	Viscous liquid	Method ID:	PHL_RPC_12C	End of analysis:	27/10/2022
Batch No.: *	DR25122298A	Method SOP:	MET-LAB-003-02	Analyst:	Blaž Janežič

<sup>\*</sup> Information provided by the client.

CANNABINOID TRACE ANALYSIS		Concentration [% w/w]	Expanded uncertainty [% w/w]	LOQ [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	3.42	0.17	0.00300	
CBDA	- Cannabidiolic acid	0.221	0.037	0.00300	I
CBGA	- Cannabigerolic acid	0.00304	0.00091	0.00300	
CBG	- Cannabigerol	0.46	0.12	0.00300	<b>I</b>
CBD	- Cannabidiol	24.5	1.2	0.03000	
THCV	- Tetrahydrocannabivarin	1.069	0.053	0.00300	
CBN	- Cannabinol	0.0060	0.0013	0.00300	<u> </u>
Δ <sup>9</sup> -THC	- Δ-9-Tetrahydrocannabinol	0.0392	0.0086	0.00300	<u> </u>
Δ <sup>8</sup> -THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	0.00300	
CBL	- Cannabicyclol	< LOQ	n/a	0.00300	
CBC	- Cannabichromene	< LOQ	n/a	0.00300	
Δ <sup>9</sup> -THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	0.00300	
CBE	- Cannabielsoin	0.193#	0.044	0.00300	
CBNV	- Cannabivarin	0.153#	0.026	0.00300	
CBCA	- Cannabichromenic acid	< LOQ #	n/a	0.00300	
CBT	- Cannabicitran	< LOQ#	n/a	0.00300	

 $\underline{\text{Units and abbreviations:}} \% \text{ w/w} = \text{weight percent, } \\ \text{LOQ} = \text{the limit of quantitation, ND} = \text{not detected, } \\ \text{n/a} = \text{not available.} \\$ 

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:	Approved by:	Authorized by:
27/10/2022	Jaya	Jany Tate
	mag. Mayko Dragan	dr. Boštjan Jančar
	Analytical Laboratory Manager	Chief Technology Officer
End of Certificate		

PharmaHemp d.o.o. | Cesta v Gorice 8 | 1000 Ljubljana | Slovenia | info@pharma-lab.eu | https://pharma-lab.eu